ACIU Stock - AC Immune S.A.
Unlock GoAI Insights for ACIU
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $27.31M | $14.80M | $3.94M | N/A | $15.43M |
| Gross Profit | $-35,261,000 | $-39,805,000 | $3.94M | N/A | $-44,056,000 |
| Gross Margin | -129.1% | -268.9% | 100.0% | N/A | -285.5% |
| Operating Income | $-52,378,000 | $-53,624,000 | $-70,847,000 | $-79,010,000 | $-61,260,000 |
| Net Income | $-50,916,000 | $-54,233,000 | $-70,753,000 | $-72,996,000 | $-61,921,000 |
| Net Margin | -186.4% | -366.4% | -1798.0% | N/A | -401.3% |
| EPS | $-0.51 | $-0.64 | $-0.85 | $-0.97 | $-0.86 |
AC Immune SA, a clinical stage biopharmaceutical company, discovers, designs, and develops medicines and diagnostic products for the prevention and treatment of neurodegenerative diseases associated with protein misfolding. Its SupraAntigen and Morphomer platforms are designed to generate vaccines, antibodies, and small molecules, which selectively interact with misfolded proteins that are common in a range of neurodegenerative diseases. The company is developing Crenezumab, a humanized, conformation-specific monoclonal antibody, which is in Phase II clinical prevention trial for the treatment of Alzheimer's disease (AD). It is also developing ACI-24, an anti-Abeta vaccine candidate that is in Phase II clinical study for AD, as well as completed Phase Ib clinical study for Down syndrome; ACI-35, an anti-Tau vaccine candidate that has completed Phase Ib clinical study; and Tau- positron emission tomography (PET) imaging tracer, which is in Phase II clinical study. In addition, the company is researching and developing small molecule Tau aggregation inhibitors for AD and NeuroOrphan indications. Further, it has discovery and preclinical stage molecules targeting range of neurodegenerative diseases, which include diagnostics targeting TDP-43, alpha-synuclein, and NLRP3. AC Immune SA has license agreements and collaborations with Genentech, Inc.; Biogen International GmbH; Janssen Pharmaceuticals, Inc.; Life Molecular Imaging SA; Eli Lilly and Company; and WuXi Biologics. The company was incorporated in 2003 and is headquartered in Lausanne, Switzerland.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 31st 2024 | BTIG Research | Initiation | Buy | $8 |
Earnings History & Surprises
ACIUEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 28, 2026 | — | — | — | — |
Q1 2026 | Mar 12, 2026 | $-0.19 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-0.22 | $-0.20 | +9.1% | ✓ BEAT |
Q3 2025 | Aug 5, 2025 | $-0.20 | $-0.25 | -25.0% | ✗ MISS |
Q2 2025 | Apr 30, 2025 | $-0.22 | $-0.21 | +4.5% | ✓ BEAT |
Q1 2025 | Mar 13, 2025 | $-0.21 | $-0.18 | +14.3% | ✓ BEAT |
Q4 2024 | Nov 5, 2024 | $-0.20 | $0.05 | +125.0% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.42 | $-0.25 | -159.5% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.15 | $-0.21 | -40.0% | ✗ MISS |
Q1 2024 | Mar 14, 2024 | $-0.07 | $-0.06 | +14.3% | ✓ BEAT |
Q4 2023 | Nov 3, 2023 | $-0.02 | $-0.20 | -754.3% | ✗ MISS |
Q3 2023 | Aug 4, 2023 | $-0.22 | $-0.22 | 0.0% | = MET |
Q2 2023 | Apr 28, 2023 | $-0.24 | $-0.23 | +4.2% | ✓ BEAT |
Q1 2023 | Mar 16, 2023 | $-0.28 | $-0.24 | +14.3% | ✓ BEAT |
Q4 2022 | Oct 28, 2022 | $-0.24 | $-0.17 | +29.2% | ✓ BEAT |
Q3 2022 | Jul 28, 2022 | $-0.24 | $-0.24 | 0.0% | = MET |
Q2 2022 | Apr 28, 2022 | $-0.23 | $-0.25 | -8.7% | ✗ MISS |
Q1 2022 | Mar 22, 2022 | $0.10 | $-0.28 | -380.0% | ✗ MISS |
Q4 2021 | Nov 8, 2021 | $-0.29 | $-0.24 | +17.2% | ✓ BEAT |
Q3 2021 | Aug 4, 2021 | $-0.22 | $-0.29 | -31.8% | ✗ MISS |
Latest News
AC Immune shares are trading higher after the company announced interim safety and efficacy results from the Phase 2 VacSYn trial of its wholly-owned anti-alpha-synuclein active immunotherapy ACI-7104.056 in early Parkinson's disease.
📈 PositiveAC Immune surges on positive mid-stage trial data for Parkinson's drug
📈 PositiveTrading Halt: Halt status updated at 7:25:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralAC Immune Announces Interim Safety And Efficacy Results From Phase 2 VacSYn Trial Of Its Wholly-Owned Anti-Alpha-Synuclein Active Immunotherapy ACI-7104.056 In Early Parkinson's Disease
📈 PositiveTrading Halt: Halted at 6:55:00 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralBTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
📈 PositiveAC Immune Q3 EPS $(0.20) Beats $(0.22) Estimate, Sales $1.174M Miss $1.520M Estimate
➖ NeutralAC Immune SA shares are trading higher after the company released preclinical data on brain positron emission tomography tracers for imaging TDP-43 pathology ACI-19626 showing the candidate demonstrated high specificity, selectivity for target.
📈 PositiveAC Immune's Preclinical Data On Brain Positron Emission Tomography Tracers For Imaging Tdp-43 Pathology ACI-19626 Candidate Demonstrates High Specificity, Selectivity For Target
📈 PositiveAC Immune Publishes Phase 1b/2a ACI-35.030 Anti-pTau Results In eBioMedicine; Rapid Durable Response, Clean Safety; Advancing To Phase 2b ReTain
📈 PositiveBTIG Reiterates Buy on AC Immune, Maintains $8 Price Target
📈 PositiveAC Immune Sharpens Pipeline Focus With 30% Workforce Reduction And CHF 127.1M Cash Extending Runway To End Of Q3 2027
📉 NegativeFrequently Asked Questions about ACIU
What is ACIU's current stock price?
What is the analyst price target for ACIU?
What sector is AC Immune S.A. in?
What is ACIU's market cap?
Does ACIU pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ACIU for comparison